PMID- 31174841
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20211204
IS  - 2405-8025 (Electronic)
IS  - 2405-8033 (Print)
IS  - 2405-8025 (Linking)
VI  - 5
IP  - 5
DP  - 2019 May
TI  - YAP/TAZ Signaling and Resistance to Cancer Therapy.
PG  - 283-296
LID - S2405-8033(19)30028-7 [pii]
LID - 10.1016/j.trecan.2019.02.010 [doi]
AB  - Drug resistance is a major challenge in cancer treatment. Emerging evidence 
      indicates that deregulation of YAP/TAZ signaling may be a major mechanism of 
      intrinsic and acquired resistance to various targeted and chemotherapies. 
      Moreover, YAP/TAZ-mediated expression of PD-L1 and multiple cytokines is pivotal 
      for tumor immune evasion. While direct inhibitors of YAP/TAZ are still under 
      development, FDA-approved drugs that indirectly block YAP/TAZ activation or 
      critical downstream targets of YAP/TAZ have shown promise in the clinic in 
      reducing therapy resistance. Finally, BET inhibitors, which reportedly block 
      YAP/TAZ-mediated transcription, present another potential venue to overcome 
      YAP/TAZ-induced drug resistance.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Nguyen, Chan D K
AU  - Nguyen CDK
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 
      Washington, DC, USA.
FAU - Yi, Chunling
AU  - Yi C
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 
      Washington, DC, USA. Electronic address: cy232@georgetown.edu.
LA  - eng
GR  - P30 CA051008/CA/NCI NIH HHS/United States
GR  - P50 CA101942/CA/NCI NIH HHS/United States
GR  - R01 CA187090/CA/NCI NIH HHS/United States
GR  - T32 CA009686/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190327
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (YY1AP1 protein, human)
RN  - EC 2.3.- (Acyltransferases)
RN  - EC 2.3.1.- (TAFAZZIN protein, human)
SB  - IM
MH  - Acyltransferases
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Biomarkers, Tumor
MH  - Cell Cycle Proteins/*metabolism
MH  - *Drug Resistance, Neoplasm/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Molecular Targeted Therapy
MH  - Neoplasms/etiology/*metabolism/pathology/therapy
MH  - *Signal Transduction
MH  - Transcription Factors/*metabolism
PMC - PMC6557283
MID - NIHMS1525527
OTO - NOTNLM
OT  - Cancer therapy resistance
OT  - Hippo pathway
OT  - TAZ
OT  - YAP
EDAT- 2019/06/09 06:00
MHDA- 2020/07/02 06:00
PMCR- 2020/05/01
CRDT- 2019/06/09 06:00
PHST- 2018/11/10 00:00 [received]
PHST- 2018/12/31 00:00 [revised]
PHST- 2019/02/15 00:00 [accepted]
PHST- 2019/06/09 06:00 [entrez]
PHST- 2019/06/09 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - S2405-8033(19)30028-7 [pii]
AID - 10.1016/j.trecan.2019.02.010 [doi]
PST - ppublish
SO  - Trends Cancer. 2019 May;5(5):283-296. doi: 10.1016/j.trecan.2019.02.010. Epub 
      2019 Mar 27.